| scholarly article | Q13442814 |
| P356 | DOI | 10.1128/IAI.70.8.4471-4476.2002 |
| P953 | full work available at URL | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC128198 |
| P932 | PMC publication ID | 128198 |
| P698 | PubMed publication ID | 12117958 |
| P50 | author | Clemens Kocken | Q28913773 |
| Annemarie Voorberg-van der Wel | Q45380667 | ||
| Augusto Valderrama | Q55174934 | ||
| Michael J Blackman | Q56786712 | ||
| Chrislaine Withers-Martinez | Q87837775 | ||
| Fiona Hackett | Q107404870 | ||
| Alan W Thomas | Q121769890 | ||
| P2093 | author name string | Martin A Dubbeld | |
| P2860 | cites work | Integral membrane protein located in the apical complex of Plasmodium falciparum | Q24633619 |
| Human malaria parasites in continuous culture | Q28131626 | ||
| Immunization with parasite-derived apical membrane antigen 1 or passive immunization with a specific monoclonal antibody protects BALB/c mice against lethal Plasmodium yoelii yoelii YM blood-stage infection | Q34004431 | ||
| Specificity of the protective antibody response to apical membrane antigen 1 | Q34007362 | ||
| Protective immune responses to apical membrane antigen 1 of Plasmodium chabaudi involve recognition of strain-specific epitopes | Q35513031 | ||
| High-level expression of Plasmodium vivax apical membrane antigen 1 (AMA-1) in Pichia pastoris: strong immunogenicity in Macaca mulatta immunized with P. vivax AMA-1 and adjuvant SBAS2. | Q39509106 | ||
| High prevalence of natural antibodies against Plasmodium falciparum 83-kilodalton apical membrane antigen (PF83/AMA-1) as detected by capture-enzyme-linked immunosorbent assay using full-length baculovirus recombinant PF83/AMA-1. | Q40693588 | ||
| Refocusing neutralizing antibody response by targeted dampening of an immunodominant epitope. | Q41103077 | ||
| Structural studies on a putative protective Plasmodium knowlesi merozoite antigen | Q41925718 | ||
| Molecular characterisation of Plasmodium reichenowi apical membrane antigen-1 (AMA-1), comparison with P. falciparum AMA-1, and antibody-mediated inhibition of red cell invasion. | Q42632486 | ||
| Immunisation with recombinant AMA-1 protects mice against infection with Plasmodium chabaudi | Q44994461 | ||
| Precise timing of expression of a Plasmodium falciparum-derived transgene in Plasmodium berghei is a critical determinant of subsequent subcellular localization | Q47831682 | ||
| PCR-based gene synthesis as an efficient approach for expression of the A+T-rich malaria genome. | Q47857173 | ||
| Proteolytic processing and primary structure of Plasmodium falciparum apical membrane antigen-1. | Q47884690 | ||
| Vaccination trials in rhesus monkeys with a minor, invariant, Plasmodium knowlesi 66 kD merozoite antigen | Q47909837 | ||
| The Fab fragments of monoclonal IgG to a merozoite surface antigen inhibit Plasmodium knowlesi invasion of erythrocytes | Q47983326 | ||
| Protective immunity induced in squirrel monkeys with recombinant apical membrane antigen-1 of Plasmodium fragile. | Q48005602 | ||
| Differential localization of full-length and processed forms of PF83/AMA-1 an apical membrane antigen of Plasmodium falciparum merozoites. | Q48006353 | ||
| The disulfide bond structure of Plasmodium apical membrane antigen-1. | Q48033627 | ||
| Diversity of the vaccine candidate AMA-1 of Plasmodium falciparum | Q48065126 | ||
| Analysis of variation in PF83, an erythrocytic merozoite vaccine candidate antigen of Plasmodium falciparum | Q48255494 | ||
| Rat monoclonal antibodies which inhibit the in vitro multiplication of Plasmodium knowlesi | Q56381024 | ||
| Genetic conservation of the Plasmodium falciparum apical membrane antigen-1 (AMA-1) | Q64134650 | ||
| P433 | issue | 8 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | malaria | Q12156 |
| antibody | Q79460 | ||
| vaccine | Q134808 | ||
| malaria vaccine | Q6741353 | ||
| Plasmodium falciparum | Q311383 | ||
| erythrocyte invasion | Q122665572 | ||
| P1104 | number of pages | 6 | |
| P304 | page(s) | 4471-4476 | |
| P577 | publication date | 2002-08-01 | |
| P1433 | published in | Infection and Immunity | Q6029193 |
| P1476 | title | High-level expression of the malaria blood-stage vaccine candidate Plasmodium falciparum apical membrane antigen 1 and induction of antibodies that inhibit erythrocyte invasion | |
| P478 | volume | 70 |
| Q35877857 | A Library of Plasmodium vivax Recombinant Merozoite Proteins Reveals New Vaccine Candidates and Protein-Protein Interactions |
| Q36710710 | A diversity-covering approach to immunization with Plasmodium falciparum apical membrane antigen 1 induces broader allelic recognition and growth inhibition responses in rabbits |
| Q46423309 | A human phase 1 vaccine clinical trial of the Plasmodium falciparum malaria vaccine candidate apical membrane antigen 1 in Montanide ISA720 adjuvant |
| Q36141540 | A novel approach to identifying patterns of human invasion-inhibitory antibodies guides the design of malaria vaccines incorporating polymorphic antigens |
| Q37529646 | A novel malaria vaccine candidate antigen expressed in Tetrahymena thermophila. |
| Q47948366 | A recombinant vaccine based on domain II of Plasmodium vivax Apical Membrane Antigen 1 induces high antibody titres in mice. |
| Q27973519 | A role for apical membrane antigen 1 during invasion of hepatocytes by Plasmodium falciparum sporozoites |
| Q44397889 | A single malaria merozoite serine protease mediates shedding of multiple surface proteins by juxtamembrane cleavage |
| Q43986541 | Adenovectors induce functional antibodies capable of potent inhibition of blood stage malaria parasite growth |
| Q34145333 | Advances and challenges in malaria vaccine development. |
| Q35739071 | Age-dependent IgG subclass responses to Plasmodium falciparum EBA-175 are differentially associated with incidence of malaria in Mozambican children |
| Q39362577 | Allele Frequency-Based Analyses Robustly Map Sequence Sites Under Balancing Selection in a Malaria Vaccine Candidate Antigen |
| Q33558449 | Allele specificity of naturally acquired antibody responses against Plasmodium falciparum apical membrane antigen 1. |
| Q34290806 | Allelic diversity and naturally acquired allele-specific antibody responses to Plasmodium falciparum apical membrane antigen 1 in Kenya |
| Q33402457 | An inhibitory antibody blocks interactions between components of the malarial invasion machinery |
| Q55475163 | Analysis of Plasmodium vivax Apical Membrane Antigen-1 (PvAMA-1) Haplotypes among Iranian Isolates. |
| Q56368212 | Analysis of factors affecting the variability of a quantitative suspension bead array assay measuring IgG to multiple Plasmodium antigens |
| Q36906995 | Analysis of the dose-dependent stage-specific in vitro efficacy of a multi-stage malaria vaccine candidate cocktail |
| Q33761687 | Antibodies against multiple merozoite surface antigens of the human malaria parasite Plasmodium falciparum inhibit parasite maturation and red blood cell invasion |
| Q33197101 | Antibodies to malaria peptide mimics inhibit Plasmodium falciparum invasion of erythrocytes |
| Q34827195 | Antibodies to polymorphic invasion-inhibitory and non-Inhibitory epitopes of Plasmodium falciparum apical membrane antigen 1 in human malaria |
| Q45325016 | Assessment of the Combined Effect of Epstein-Barr Virus and Plasmodium falciparum Infections on Endemic Burkitt Lymphoma Using a Multiplex Serological Approach |
| Q34719080 | Association of IL-4 and IL-10 maternal haplotypes with immune responses to P. falciparum in mothers and newborns |
| Q37635335 | Avidity of anti-malarial antibodies inversely related to transmission intensity at three sites in Uganda |
| Q39015319 | Babesia bovis merozoites invade human, ovine, equine, porcine and caprine erythrocytes by a sialic acid-dependent mechanism followed by developmental arrest after a single round of cell fission |
| Q43087423 | Bioinformatic Identification of Peptidomimetic-Based Inhibitors against Plasmodium falciparum Antigen AMA1. |
| Q36594057 | Breadth and magnitude of antibody responses to multiple Plasmodium falciparum merozoite antigens are associated with protection from clinical malaria |
| Q37253541 | Cell-mediated immunity elicited by the blood stage malaria vaccine apical membrane antigen 1 in Malian adults: results of a Phase I randomized trial |
| Q36862490 | Cohort study of the association of antibody levels to AMA1, MSP119, MSP3 and GLURP with protection from clinical malaria in Ghanaian children |
| Q28278882 | Comparative genomic analysis and phylogenetic position of Theileria equi |
| Q36898029 | Comparative testing of six antigen-based malaria vaccine candidates directed toward merozoite-stage Plasmodium falciparum |
| Q80834997 | Correlation of structural development and differential expression of invasion-related molecules in schizonts of Plasmodium falciparum |
| Q35606847 | Crystal structure of Plasmodium knowlesi apical membrane antigen 1 and its complex with an invasion-inhibitory monoclonal antibody |
| Q34598177 | Cytokine and antibody responses to Plasmodium falciparum in naïve individuals during a first malaria episode: effect of age and malaria exposure |
| Q47883813 | Detailed functional characterization of glycosylated and nonglycosylated variants of malaria vaccine candidate PfAMA1 produced in Nicotiana benthamiana and analysis of growth inhibitory responses in rabbits |
| Q55342398 | Development of a high-throughput flexible quantitative suspension array assay for IgG against multiple Plasmodium falciparum antigens. |
| Q49353060 | Development of quantitative suspension array assays for six immunoglobulin isotypes and subclasses to multiple Plasmodium falciparum antigens |
| Q47859315 | Direct effect of Plasmodium vivax recombinant vaccine candidates AMA-1 and MSP-119 on the innate immune response |
| Q48013866 | Distinct mechanisms govern proteolytic shedding of a key invasion protein in apicomplexan pathogens |
| Q33859217 | Distinct patterns of diversity, population structure and evolution in the AMA1 genes of sympatric Plasmodium falciparum and Plasmodium vivax populations of Papua New Guinea from an area of similarly high transmission |
| Q47311278 | EDiP: the Epitope Dilution Phenomenon. Lessons learnt from a malaria vaccine antigen and its applicability to polymorphic antigens |
| Q35802357 | Effect of codon optimization on expression levels of a functionally folded malaria vaccine candidate in prokaryotic and eukaryotic expression systems |
| Q37427474 | Erythrocyte invasion by Babesia bovis merozoites is inhibited by polyclonal antisera directed against peptides derived from a homologue of Plasmodium falciparum apical membrane antigen 1. |
| Q47986453 | Evaluation of the genetic diversity of domain II of Plasmodium vivax Apical Membrane Antigen 1 (PvAMA-1) and the ensuing strain-specific immune responses in patients from Sri Lanka |
| Q37135480 | Expression and purification of an engineered, yeast-expressed Leishmania donovani nucleoside hydrolase with immunogenic properties |
| Q39518664 | Extensive antigenic polymorphism within the repeat sequence of the Plasmodium falciparum merozoite surface protein 1 block 2 is incorporated in a minimal polyvalent immunogen |
| Q34994491 | Finding the sweet spots of inhibition: understanding the targets of a functional antibody against Plasmodium vivax Duffy binding protein |
| Q48037113 | Fine mapping of an epitope recognized by an invasion-inhibitory monoclonal antibody on the malaria vaccine candidate apical membrane antigen 1. |
| Q42006881 | Functional analysis of Plasmodium falciparum apical membrane antigen 1 utilizing interspecies domains |
| Q37313879 | Genetic diversity and malaria vaccine design, testing and efficacy: preventing and overcoming 'vaccine resistant malaria'. |
| Q37348151 | Genetic diversity of the Plasmodium falciparum apical membrane antigen I gene in parasite population from the China-Myanmar border area |
| Q39730124 | Geographical structure of diversity and differences between symptomatic and asymptomatic infections for Plasmodium falciparum vaccine candidate AMA1. |
| Q35037036 | Global Population Structure of the Genes Encoding the Malaria Vaccine Candidate, Plasmodium vivax Apical Membrane Antigen 1 (PvAMA1). |
| Q41722962 | Heterologous expression of Plasmodium vivax apical membrane antigen 1 (PvAMA1) for binding peptide selection. |
| Q34965654 | High antibody responses against Plasmodium falciparum in immigrants after extended periods of interrupted exposure to malaria |
| Q33898336 | High yield expression of an AHL-lactonase from Bacillus sp. B546 in Pichia pastoris and its application to reduce Aeromonas hydrophila mortality in aquaculture |
| Q39362569 | Human antibodies to recombinant protein constructs of Plasmodium falciparum Apical Membrane Antigen 1 (AMA1) and their associations with protection from malaria |
| Q28727698 | Humoral immune responses to a single allele PfAMA1 vaccine in healthy malaria-naïve adults |
| Q36421572 | Humoral responses to plasmodium falciparum blood-stage antigens and association with incidence of clinical malaria in children living in an area of seasonal malaria transmission in Burkina Faso, West Africa. |
| Q36984161 | Identification and prioritization of merozoite antigens as targets of protective human immunity to Plasmodium falciparum malaria for vaccine and biomarker development |
| Q92292593 | Identification of adjuvants for clinical trials performed with Plasmodium falciparum AMA1 in rabbits |
| Q35683634 | Identification of an Immunogenic Mimic of a Conserved Epitope on the Plasmodium falciparum Blood Stage Antigen AMA1 Using Virus-Like Particle (VLP) Peptide Display |
| Q53819699 | IgM and IgG against Plasmodium falciparum lysate as surrogates of malaria exposure and protection during pregnancy. |
| Q48031825 | Immune responses in mice induced by prime-boost schemes of the Plasmodium falciparum apical membrane antigen 1 (PfAMA1)-based DNA, protein and recombinant modified vaccinia Ankara vaccines |
| Q44367636 | Immunogenicity of a recombinant malaria vaccine candidate, domain I+II of AMA-1 ectodomain, from Indian P. falciparum alleles |
| Q34601683 | Immunoglobulin G antibodies to merozoite surface antigens are associated with recovery from chloroquine-resistant Plasmodium falciparum in Gambian children |
| Q46140366 | Immunological profile of a Plasmodium vivax AMA-1 N-terminus peptide-carbon nanotube conjugate in an infected Plasmodium berghei mouse model |
| Q35439859 | Impact of malaria preexposure on antiparasite cellular and humoral immune responses after controlled human malaria infection |
| Q35330733 | Impact of the RTS,S malaria vaccine candidate on naturally acquired antibody responses to multiple asexual blood stage antigens |
| Q36314049 | In immunization with Plasmodium falciparum apical membrane antigen 1, the specificity of antibodies depends on the species immunized |
| Q30967137 | Induction of parasite growth-inhibitory antibodies by a virosomal formulation of a peptidomimetic of loop I from domain III of Plasmodium falciparum apical membrane antigen 1 |
| Q33214292 | Induction of strain-transcending immunity against Plasmodium chabaudi adami malaria with a multiepitope DNA vaccine |
| Q36349656 | Invasion-inhibitory antibodies inhibit proteolytic processing of apical membrane antigen 1 of Plasmodium falciparum merozoites |
| Q34011922 | Lack of allele-specific efficacy of a bivalent AMA1 malaria vaccine |
| Q34416904 | Limited antigenic diversity of Plasmodium falciparum apical membrane antigen 1 supports the development of effective multi-allele vaccines |
| Q36297353 | Low antibodies against Plasmodium falciparum and imbalanced pro-inflammatory cytokines are associated with severe malaria in Mozambican children: a case-control study |
| Q37566118 | Malaria epidemiology in central Myanmar: identification of a multi-species asymptomatic reservoir of infection |
| Q36313955 | Malaria vaccine-related benefits of a single protein comprising Plasmodium falciparum apical membrane antigen 1 domains I and II fused to a modified form of the 19-kilodalton C-terminal fragment of merozoite surface protein 1 |
| Q36219634 | Malaria vaccines in development |
| Q28730794 | Measurement of the plasma levels of antibodies against the polymorphic vaccine candidate apical membrane antigen 1 in a malaria-exposed population. |
| Q54253318 | Micro-epidemiology of malaria in an elimination setting in Central Vietnam. |
| Q37172956 | Mixed allele malaria vaccines: host protection and within-host selection |
| Q42727356 | Mode of action of invasion-inhibitory antibodies directed against apical membrane antigen 1 of Plasmodium falciparum |
| Q43075976 | Molecules incorporating a benzothiazole core scaffold inhibit the N-myristoyltransferase of Plasmodium falciparum. |
| Q35628510 | Multiple clinical episodes of Plasmodium falciparum malaria in a low transmission intensity setting: exposure versus immunity |
| Q39278961 | Multiple splice variants encode a novel adenylyl cyclase of possible plastid origin expressed in the sexual stage of the malaria parasite Plasmodium falciparum |
| Q40120062 | Multiplexing detection of IgG against Plasmodium falciparum pregnancy-specific antigens |
| Q37647647 | Naturally Acquired Binding-Inhibitory Antibodies to Plasmodium vivax Duffy Binding Protein in Pregnant Women Are Associated with Higher Birth Weight in a Multicenter Study |
| Q36302325 | Opinion: antibody-based therapies for malaria |
| Q44941813 | Optimization of a multi-stage, multi-subunit malaria vaccine candidate for the production in Pichia pastoris by the identification and removal of protease cleavage sites |
| Q55292950 | Optimization of incubation conditions of Plasmodium falciparum antibody multiplex assays to measure IgG, IgG1-4, IgM and IgE using standard and customized reference pools for sero-epidemiological and vaccine studies. |
| Q24802878 | Optimized expression of Plasmodium falciparum erythrocyte membrane protein 1 domains in Escherichia coli |
| Q33742070 | Plasmodium berghei circumvents immune responses induced by merozoite surface protein 1- and apical membrane antigen 1-based vaccines |
| Q27972559 | Plasmodium falciparum AMA1 binds a rhoptry neck protein homologous to TgRON4, a component of the moving junction in Toxoplasma gondii |
| Q37103927 | Plasmodium falciparum malaria vaccines in development |
| Q92664225 | Plasmodium falciparum merozoite surface antigen-specific cytophilic IgG and control of malaria infection in a Beninese birth cohort |
| Q37270041 | Plasmodium falciparum merozoite surface protein 2 is unstructured and forms amyloid-like fibrils |
| Q35931132 | Polymorphisms in B Cell Co-Stimulatory Genes Are Associated with IgG Antibody Responses against Blood-Stage Proteins of Plasmodium vivax |
| Q36286806 | Population genetic structure and natural selection of apical membrane antigen-1 in Plasmodium vivax Korean isolates |
| Q36391717 | Potential impact of host immunity on malaria treatment outcome in Tanzanian children infected with Plasmodium falciparum |
| Q36446656 | Production of the subdomains of the Plasmodium falciparum apical membrane antigen 1 ectodomain and analysis of the immune response |
| Q28554439 | Production, Quality Control, Stability and Pharmacotoxicity of a Malaria Vaccine Comprising Three Highly Similar PfAMA1 Protein Molecules to Overcome Antigenic Variation |
| Q46135488 | Production, quality control, stability and pharmacotoxicity of cGMP-produced Plasmodium falciparum AMA1 FVO strain ectodomain expressed in Pichia pastoris |
| Q39518657 | Prospective identification of malaria parasite genes under balancing selection |
| Q36536645 | Prospects for recombinant vaccines against Babesia bovis and related parasites |
| Q35875731 | Proteases in host cell invasion by the malaria parasite |
| Q35094826 | Protection of Malian children from clinical malaria is associated with recognition of multiple antigens |
| Q33394245 | Safety and immunogenicity of a recombinant Plasmodium falciparum AMA1 malaria vaccine adjuvanted with Alhydrogel, Montanide ISA 720 or AS02. |
| Q33316023 | Safety and immunogenicity of an AMA-1 malaria vaccine in Malian adults: results of a phase 1 randomized controlled trial |
| Q33530106 | Safety and immunogenicity of an AMA1 malaria vaccine in Malian children: results of a phase 1 randomized controlled trial |
| Q36398138 | Sequence diversity and natural selection at domain I of the apical membrane antigen 1 among Indian Plasmodium falciparum populations |
| Q35853662 | Sero-epidemiological evaluation of Plasmodium falciparum malaria in Senegal |
| Q27681409 | Structural and Functional Insights into the Malaria Parasite Moving Junction Complex |
| Q36728063 | Targets and Mechanisms Associated with Protection from Severe Plasmodium falciparum Malaria in Kenyan Children |
| Q33294829 | The Princeton Protein Orthology Database (P-POD): a comparative genomics analysis tool for biologists |
| Q28742887 | The RON2-AMA1 interaction is a critical step in moving junction-dependent invasion by apicomplexan parasites |
| Q35241288 | The antibody response to Plasmodium falciparum Merozoite Surface Protein 4: comparative assessment of specificity and growth inhibitory antibody activity to infection-acquired and immunization-induced epitopes |
| Q27318798 | The evolutionary consequences of blood-stage vaccination on the rodent malaria Plasmodium chabaudi |
| Q37471465 | The future for blood-stage vaccines against malaria |
| Q33512926 | The quantity and quality of African children's IgG responses to merozoite surface antigens reflect protection against Plasmodium falciparum malaria |
| Q28743564 | Transgene optimization, immunogenicity and in vitro efficacy of viral vectored vaccines expressing two alleles of Plasmodium falciparum AMA1 |
| Q27336448 | Vaccination with Plasmodium knowlesi AMA1 formulated in the novel adjuvant co-vaccine HT™ protects against blood-stage challenge in rhesus macaques |
Search more.